Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma

Overview of attention for article published in Journal of Clinical Oncology, March 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

twitter: 10 X users
patent: 3 patents

guideline: 1 clinical guideline source

Readers on

mendeley: 77 Mendeley

So far, Altmetric has seen 11 X posts from 10 X users, with an upper bound of 68,507 followers.

RT @KimmelCancerCtr: In new research published in @JCO_ASCO, SKCC's Drs. Marlana Orloff & Takami Sato discuss the results of a phase I #Cli…

In new research published in @JCO_ASCO, SKCC's Drs. Marlana Orloff & Takami Sato discuss the results of a phase I #ClinicalTrial of tebentafusp, the first systemic therapy specifically for #UvealMelanoma: https://t.co/pJcsXMTrKD #ResearchWednesday #…

Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma https://t.co/XtHZm7ZnFg

In a dose-finding study for tebentafusp in uveal melanoma, common AEs were pyrexia (91%), rash (83%), pruritus (83%), nausea (74%), fatigue (71%) and chills (69%); the ORR was 11.9%, although mOS was 25 months and 1-year OS was 67%: https://t.co/MW5CSjl…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 7 additional X posts.